We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Heartware International, Inc. (MM) | NASDAQ:HTWR | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 57.98 | 57.95 | 65.00 | 0 | 01:00:00 |
From May 2019 to May 2024
FRAMINGHAM, Mass., Nov. 12, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that HeartWare President and Chief Executive Officer, Doug Godshall, is scheduled to present at the Canaccord Genuity 2015 Medical Technology & Diagnostics Forum on November 19, 2015 at 10:00 a.m. ET in New York.
A live webcast of the company's presentation at the conference will be available via a link provided at www.heartware.com. A replay of the webcast will be available for 90 days after the presentation.
About HeartWare International
HeartWare International, Inc. develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare HVAD System is approved in the United States for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, has received CE Marking in the European Union and has been used to treat patients in 47 countries. The device is also currently the subject of a U.S. clinical trial for destination therapy. For additional information, please visit www.heartware.com.
HeartWare International, Inc. is a member of the Russell 2000®, and its securities are publicly traded on The NASDAQ Stock Market.
HEARTWARE, HVAD, MVAD, PAL, SYNERGY, CIRCULITE and HeartWare logos are trademarks of HeartWare, Inc. or its affiliates.
For additional information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartware.com
Phone: +1 508 739 0864
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/heartware-presentation-at-the-canaccord-genuity-2015-medical-technology--diagnostics-forum-to-be-webcast-300177399.html
SOURCE HeartWare International, Inc.
Copyright 2015 PR Newswire
1 Year Heartware International, Inc. (MM) Chart |
1 Month Heartware International, Inc. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
